Abstract 944P
Background
Prognostic markers for nasopharyngeal cancer (NPC) are still urgently needed but current marker of Epstein-Barr virus DNA require high costs and technical requirements limit applications in patient care. Inflammatory cells play an important role in the development of a cancer and it has been shown in various solid tumors that inflammatory cells influence the patient's prognosis. COP-NLR Score of peripheral blood are easily obtained and can also reflect host inflammatory responses.
Methods
A retrospective cohort study using data from the clinical registry of NPC patients diagnosed from 2007-2016 at Dr. Sardjito Hospital Yogyakarta. Survival analysis with the Kaplan-Meier curve and Cox proportional hazard regression were used to examine the influence of age, sex, nutritional status, tumor size, node, type of therapy and COP-NLR score for 2-years overall survival of stage III-IVB NPC patients.
Results
A total of 358 stage III-IVB NPC patients were analyzed in this study. Determination of COP-NLR score using the NLR limit of 4.28 and the number of thrombocytes 496 x 103 / uL. If NLR ≤ 4.28 and platelet count ≤ 496 x 103 / uL, the score is 0. If NLR > 4.28 or platelet count > 496 x 103 / uL, the score is 1. If NLR > 4.28 and platelet count > 496 x 103 / uL, the score is 2. Two-years overall survival of patients with a score of 0, 1, 2 was 72.2%, 57.3%, and 41.4% (p = 0.002). A higher COP-NLR score (score 1&2) showed a decrease in the 2-year overall survival rate than lower score (score 0) with hazard ratio 1.887 (95% confidence interval: 1.26-2.81 and p = 0.002).
Conclusions
Locally advanced NPC patients with COP-NLR score 0 before therapy have a better 2 years overall survival rate than patients with COP-NLR scores 1 and 2.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sardjito Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.